ENYO Pharma got the USA allowance for its FXR agonist use patent in hepatitis B virus (HBV). The patent was licensed under exclusive agreement from Inserm. FXR agonists change the composition of the transcriptional complex on the HBV cccDNA resulting in repression of HBV cccDNA expression.
MIMESIS NEWSLETTER #2, December 2017
A novel systems biology approach to develop preclinical assets from innovative drug discovery starting points inspired by viruses.
MIMESIS is a research and innovation project coordinated by ENYO Pharma and funded under the highly selective H2020 – SMEInstrument – Phase 2 call that aims at: “Dedicated support to biotechnology SMEs closing the gap from lab to market”. The MIMESIS project was launched on Nov 2016 for 2 years.
ENYO Pharma is pleased to announce the initiation of a research collaboration with Professor Julian Walters at Imperial College London. The main goal of these investigations is to evaluate the potential for therapeutic use of the FXR agonist EYP001 in patients with primary bile acid diarrhoea. Primary Bile Acid Diarrhoea (BAD) is a common form of chronic diarrhoea associated with excessive faecal bile acid (BA) loss in the absence of overt ileal disease. Explants of human ileum from healthy subjects will be exposed to increasing concentrations of ENYO Pharma’s FXR agonist.
ENYO Pharma is pleased to join The Liver Forum at the Forum for Collaborative Research, “to advance the regulatory sciences for the treatment of NASH and liver fibrosis, which is emerging as a leading cause of advanced liver disease in the U.S. and worldwide” (http://www.forumresearch.org/projects/liver-forum). The Liver Forum provides an independent and neutral venue for ongoing multi-stakeholder dialogue. This project will allow our biotech to participate in fruitful meetings and discussions focused on advancing the regulatory sciences for the treatment of NASH and liver fibrosis.